How Does the New Sublingual Absorption Technology Improve Bioavailability?

Basic Mechanism

• Bypassing hepatic first-pass effect: Drugs enter venous return via the sublingual mucosa, directly entering systemic circulation and reducing hepatic metabolic loss.
• Thin, highly vascularized mucosa: Thin epithelium and dense capillary networks facilitate rapid absorption and onset of action.

Key Factors Affecting Absorption

• Molecular weight and lipophilicity: Low molecular weight and moderate lipophilic/hydrophilic balance (moderate logP) enhance mucosal permeability.
• Ionization State: Non-ionized forms typically penetrate the lipid bilayer more readily; pH modulation can increase the proportion of non-ionized species.
• Mucosal Integrity and Blood Flow: Inflammation/injury or alterations in blood flow can modify absorption.
• Dose and Contact Time: Sublingual administration has limited capacity; drugs require sufficient dwell time on the mucosa.

Novel Formulations and Technical Strategies

• Transdermal/Transmucosal Enhancers: Short-chain fatty acids, surfactants, bile salts, etc., temporarily open tight junctions or alter membrane fluidity.
• Carrier Nanotechnology: Liposomes, solid lipid nanoparticles, polymeric nanoparticles, nanocrystals, etc., enhance solubility, membrane penetration, and stability.
• Inclusion Complexes and Solubilizers: Cyclodextrins, hydrophilic carriers improve solubility and reduce irritation.
• Mucoadhesive Bases: Buccal films or adhesive tablets prolong mucosal contact time (e.g., rapid-dissolving films).
• pH Modulation and Controlled-Release Systems: Maintain optimal local pH to increase non-ionized drug fraction or provide controlled release.
• Enzyme inhibitors/protective groups (prodrugs): Inhibit mucosal enzyme degradation or design drugs as precursors for in vivo conversion.
• Solid dispersion and crystal form control: Improve dissolution rates and bioavailability.

Transdermal electroporation/electroosmosis (rarely used sublingually but conceptually enhances penetration) and local micro-delivery devices (e.g., drug-containing transdermal patches).